Published • loading... • Updated
GLP-1 drugmakers sued over sudden vision loss risk: Reports
Dozens of plaintiffs say the drugs caused NAION, and one study found 35 cases among more than 159,000 patients.
- Dozens of patients have filed Lawsuits against drugmakers Novo and Eli Lilly, alleging the companies failed to warn users about sudden vision loss from GLP-1s including Ozempic, Wegovy, Mounjaro, and Zepbound.
- Non-Arteritic anterior ischaemic optic neuropathy, or NAION, is a rare condition that can lead to sudden and sometimes permanent vision loss due to lack of blood flow to the optic nerve.
- Research involving more than 159,000 participants with type 2 diabetes found 35 cases of NAION among GLP-1 users, while Researchers also noted an increased risk of developing "Other optic nerve disorders," identified in 93 patients.
- Similar Lawsuits against Eli Lilly are currently pending, with plaintiffs claiming the company failed to adequately warn patients of potential risks associated with their weight-loss and diabetes treatments.
- The American Academy of Ophthalmology encourages clinicians and patients to make "informed choices" regarding GLP-1s; While studies show modest risk, fewer patients experienced sight-threatening complications from the disease.
Insights by Ground AI
12 Articles
12 Articles
Vision loss concerns spark US lawsuits as Australian bodies issue advice on GLP-1 drugs
RANZCO and OA said patients should not stop or delay GLP-1 treatment. Image: millat/stock.adobe.com.Australians taking glucagon-like-peptide-1 receptor agonist (GLP-1) medications have been advised they do not need to stop treatment solely due to concerns about a rare form of vision loss, amid growing litigation in the US among patients who believe the weight loss drug has damaged their eye health. The Australian advice comes as authorities war…
Coverage Details
Total News Sources12
Leaning Left0Leaning Right0Center11Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
